Bruno C. Medeiros - Concepedia

Author

Bruno C. Medeiros

Also Known As

B C Medeiros, B Medeiros, B. C. Medeiros, B. Medeiros, B.C. De Medeiros, B.C. Medeiros, B.C. de Medeiros, Barbara Maria Souza de Medeiros, Benjamin Medeiros, Bruno C Medeiros

347

Publications

15.7K

Citations

H-Index

Concepts

All Affiliations

Stanford University Fred Hutch Cancer Center Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center University of Colorado Denver

About

Bruno C. Medeiros is an author at Stanford University specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	37	4.9K
2	Health Sciences	11	11	1.4K
3	Engineering	3	3	372
4	Nursing	1	1	137
5	Public Health	1	1	36

Bruno C. Medeiros

115

Publications

14.1K

Citations

H-Index

Page 1

	Year	Citations
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford, New England Journal of Medicine	2017	2.1K
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Blood	2017	1.4K
Functional genomic landscape of acute myeloid leukaemia Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly, Nature Hematological MalignancyChromatinFunctional GenomicsMixed-phenotype Acute LeukemiaGenetics	2018	1.4K
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPharmacotherapyMetronomic ChemotherapyMyeloid NeoplasiaHematological Malignancy	2018	958
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission M. Ryan Corces, Wan‐Jen Hong, Irving L. Weissman, Proceedings of the National Academy of Sciences	2014	688
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia Steven M. Chan, Danièl Thomas, M. Ryan Corces, Nature Medicine Hematological MalignancyIsocitrate Dehydrogenase 1Mixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaGenetics	2015	563
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study Lene Sofie Granfeldt Østgård, Bruno C. Medeiros, Henrik Sengeløv, Journal of Clinical Oncology	2015	436
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia Alyssa Carey, David K. Edwards, Christopher A. Eide, Cell Reports	2017	257
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States Bruno C. Medeiros, Sacha Satram‐Hoang, Deborah Hurst, Annals of Hematology EngineeringElderly PatientsMixed-phenotype Acute LeukemiaPrognosisUnited States	2015	253
Pevonedistat (<scp>MLN</scp>4924), a First‐in‐Class <scp>NEDD</scp>8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study Ronan Swords, Harry P. Erba, Daniel J. DeAngelo, British Journal of Haematology	2015	234

Page 1